Holen Sie sich die Stockscreener-App
26.75
0.91%
0.24
Schlusskurs vom Vortag:
$26.51
Offen:
$26.64
24-Stunden-Volumen:
1.23M
Relative Volume:
0.57
Marktkapitalisierung:
$2.76B
Einnahmen:
$164.01M
Nettoeinkommen (Verlust:
$-65.04M
KGV:
-38.94
EPS:
-0.687
Netto-Cashflow:
$-383.84M
1W Leistung:
-2.66%
1M Leistung:
-13.40%
6M Leistung:
-4.19%
1J Leistung:
+51.73%
1-Tages-Spanne:
$25.71
$26.88
1-Wochen-Bereich:
$25.71
$27.95
52-Wochen-Spanne:
$15.60
$38.26
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
26.75 | 2.76B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-09 | Eingeleitet | Jefferies | Buy |
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake - Stock Titan
Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position - Stock Titan
Equities Analysts Offer Predictions for BEAM Q3 Earnings - MarketBeat
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
Analyst Forecasts Just Became More Bearish On Beam Therapeutics Inc. (NASDAQ:BEAM) - simplywall.st
Weekly Recap: H1 2026 financials and BEAM-302 pivotal cohort dosing - TradingView
Beam Therapeutics Inc. $BEAM Shares Acquired by Janus Henderson Group PLC - MarketBeat
(BEAM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Beam Therapeutics (NASDAQ:BEAM) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results - webull.com
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics Inc (BEAM) Stock News Today - TradingKey
First Trust Advisors LP Increases Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $43 to $78 - moomoo.com
RBC Capital Keeps Their Hold Rating on Beam Therapeutics (BEAM) - The Globe and Mail
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM) - The Globe and Mail
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus - Yahoo Finance
Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $51.07, Implies 80% Upside - TradingView
BofA Adjusts Price Target on Beam Therapeutics to $43 From $47 - marketscreener.com
BEAM SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Beam Therapeutics completes dosing in sickle cell trial - Investing.com
Beam Therapeutics completes dosing in sickle cell trial By Investing.com - Investing.com South Africa
Beam Therapeutics (NASDAQ:BEAM) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Beam Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary - TradingView
Beam Therapeutics (Nasdaq: BEAM) holds $1.2B cash, plans risto-cel BLA - Stock Titan
Beam Therapeutics reports Q2 2026 results: $1.15B cash, $122.7M net loss - TradingView
Beam Therapeutics (NASDAQ: BEAM) details Q2 loss, $1.2B cash and pipeline plans - Stock Titan
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) - marketscreener.com
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Potential 101.88% Upside in the Biotech Arena - directorstalkinterviews.com
Beam Therapeutics: A Valuation With Upside Left (NASDAQ:BEAM) - Seeking Alpha
Dimensional Fund Advisors LP Has $51.33 Million Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Renaissance Technologies LLC Boosts Stake in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc. $BEAM Shares Sold by Liontrust Investment Partners LLP - MarketBeat
Beam Therapeutics (BEAM) CMO sells 16,667 shares under 10b5-1 plan - Stock Titan
Beam Therapeutics (BEAM) to Release Earnings on Tuesday - MarketBeat
Beam Therapeutics (BEAM) insider Amy Simon plans sale of 16,677 common shares - Stock Titan
Beam Therapeutics (BEAM) Revenue BreakdownMain Composition - Moomoo
TradingKey - TradingKey
Beam Therapeutics Inc (BEAM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beam Therapeutics Inc (BEAM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BEAM|Beam Therapeutics Inc|Price:25.100|Chg%:-0.810 - TradingKey
Beam Therapeutics Inc (BEAM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beam Therapeutics Inc. (BEAM) stock price, news, quote and history - Yahoo Finance Australia
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):